A market update credits new generics and steady prices for the rise in sales value, with Eli Lilly's tirzepatide featured in the numbers.
Recap by typeshit. Post by Facebook on Facebook.
An explainer on talking to a provider about whether Wegovy fits you, plus a reminder that insurance may not pay for it.
Khunti shares real-world data on over a million UK adults using telehealth for obesity care, where 90% started on tirzepatide before a major price hike changed prescribing.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
Novo Nordisk is cutting what Wegovy costs in China, Polskie Radio reports. Tap through for the size of the cut and when it takes effect.
Across 73,592 matched pairs, starting a GLP-1 drug instead of a DPP-4 inhibitor was linked to slower frailty and a 13% lower fall rate.
A law firm backed explainer that notes 4,025 cases pending in MDL 3094 as of October 2026, with no trials or settlements yet, alongside a case review pitch.
Loading…